Retatrutide Beats Ozempic on Weight Loss in Lilly’s Phase 3 Diabetes Trial

New TRANSCEND-T2D-2 results put retatrutide directly against injectable semaglutide in type 2 diabetes. The weight-loss difference is substantial, but the trial design, statistical caveats, and tolerability results matter.

For research use only. Not for human consumption.